Serum Institute of India: News
Adar Poonawalla acquires half of KJo's Dharma Productions for ₹1,000cr
In a major development, Adar Poonawalla, the CEO of Serum Institute of India, will be buying a 50% stake in Dharma Productions and Dharmatic Entertainment.
AstraZeneca says it will withdraw Covid-19 vaccine globally
The United Kingdom-based pharmaceutical company, AstraZeneca, on Tuesday said that it has initiated a worldwide recall of Covid-19 vaccine.
Serum Institute partners with Oxford University to combat Meningitis-B
The Serum Institute of India has entered into a five-year licensing deal with the University of Oxford, according to a press release on Tuesday (April 16).
India set to launch HPV vaccination campaign for girls: Report
The government is preparing to launch a human papillomavirus (HPV) vaccination drive for girls in the age group of 9-14 years, The Indian Express reported.
Adar Poonawalla buys London's most expensive house for Rs. 1,446cr
Billionaire Adar Poonawalla, the CEO of Serum Institute of India (SII), has reportedly finalized a deal to buy London's priciest house sold this year, worth £138 million (Rs. 1,446 crore).
R21: The new malaria vaccine you must know about
A groundbreaking new vaccine has been developed for malaria, and it is causing a stir in the global health community.
Serum Institute seeks DCGI's approval for Covovax as booster dose
The Serum Institute of India (SII) has sought the Drugs Controller General of India's (DCGI) approval to roll out its Covovax in the market as a booster dose for adults.
India's 100 richest amassed $25bn more wealth in 2022: Forbes
While the rupee has weakened, raising concerns of inflation and looming recession for the rest of the Indians, it has seemingly no effect on the country's richest bunch.
Covishield manufacturer SII duped of Rs. 1 crore, 7 arrested
In a major cheating and cyber fraud case, the Serum Institute of India (SII) has been duped of Rs. 1 crore.
Covishield death: Bombay HC notice to Centre, Serum Institute, DCGI
A man has filed a compensation suit against the Indian vaccine maker Serum Institute of India (SII) for Rs. 1,000 crore, claiming that the side effects of the Covishield vaccine killed his daughter last year.
India to get its first indigenous cervical cancer vaccine today
India is all set to get its first indigenous cervical cancer vaccine this week.
Is SII developing vaccine for monkeypox? Here's what Poonawalla said
Amid the rising monkeypox scare, Serum Institute of India (SII) CEO Adar Poonawalla said on Tuesday they are in talks with American biotech company Novavax to develop a messenger RNA (mRNA) vaccine for it.
India inching closer to launching its first dengue vaccine
India is likely to get its first vaccine for Dengue soon as the Indian Council of Medical Research (ICMR) is all set to submit its clinical trial protocol to the country's drug regulator CDSCO by June.
COVID-19 vaccine precautionary dose service charge capped at Rs. 150
The Centre on Saturday announced that private vaccination centers can charge a service fee of up to Rs. 150 in addition to the cost of the precautionary dose of the COVID-19 vaccine from beneficiaries.
DCGI approves emergency use of Covovax in children above 12
The Drugs Controller General of India (DCGI) has granted Emergency Use Authorisation to the coronavirus vaccine Covovax for restricted emergency use in children above the age of 12.
Govt panel okays phase-3 trials of Covovax as booster dose
The subject expert committee (SEC) of India's drug regulatory authority Central Drugs Standard Control Organization (CDSCO) has recommended phase-3 clinical trials of Covovax as a booster dose against COVID-19 in adults, Mint reported.
Only faster COVID-19 vaccinations can end pandemic: Adar Poonawalla
Billions need to be vaccinated at a faster rate to reach the end of the COVID-19 pandemic, said Adar Poonawalla, CEO of the Serum Institute of India (SII), which manufactures the COVID-19 vaccine Covishield.
SII to launch COVID-19 vaccine for children in 6 months
The Serum Institute of India is looking to launch a COVID-19 vaccine for children in six months, SII CEO Adar Poonawalla said Tuesday.
COVID-19 vaccine: Study finds AstraZeneca booster jab safe, effective
Seven COVID-19 vaccines are safe and stimulate a strong immune response when used as a booster jab to those who have already vaccinated, a study published in The Lancet said.
Are Indian vaccines effective against Omicron? Here's what manufacturers say
The COVID-19 vaccine manufacturers in India are reportedly waiting for "more data" on the new coronavirus variant, Omicron, to assess the efficacy of their vaccines.
Serum gets nod for Novavax trial in 7-11 age group
The Serum Institute of India (SII) has received the approval to conduct trials of the Novavax COVID-19 vaccine in children aged between seven and 11 years.
SII's Poonawalla bats for booster dose, opposes mixing of vaccines
Serum Institute of India Chairman Cyrus Poonawalla on Friday said that taking a third or booster dose of Covishield, the coronavirus vaccine manufactured by his firm was desirable.
EU body says it didn't receive application for Covishield approval
The European Medicines Agency (EMA) said it has not received any application for the authorization of the coronavirus vaccine Covishield.
COVID-19: Serum to start producing Sputnik V vaccine from September
The Serum Institute of India (SII) will begin producing the Russian COVID-19 vaccine, Sputnik V, from September, the Russian Direct Investment Fund (RDIF) announced today.
Expert panel says no to Covovax's children trials in India
A Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has denied permission to Pune-based Serum Institute of India (SII) for conducting clinical trials of its second COVID-19 vaccine, Covovax, in children.
'Not received Covishield approval request,' says EU body amid concerns
The Serum Institute of India (SII) has not yet applied for the approval of its coronavirus vaccine Covishield in the "Green Pass" issued by the European Union, according to a statement from the EU.
Serum to begin Covovax trials on children in July
The Serum Institute of India (SII) will soon apply for regulatory approval to conduct clinical trials of Covovax on children in India.
Efforts on to restart AstraZeneca shipments from India: WHO official
The WHO is urgently trying to work with AstraZeneca, Serum Institute of India (SII) as well as the Indian government to restart shipments of COVID-19 vaccines to countries, a senior official at the UN health agency said.
Covovax India launch by September; trial for kids soon: SII
The Serum Institute of India (SII) is looking to launch the COVID-19 vaccine developed by the United States firm Novavax in India by September.
After Pfizer and Moderna, Serum seeks indemnity over COVID-19 vaccine
The Serum Institute of India has requested the Indian government to provide it indemnity from liability in connection with its COVID-19 vaccines, company sources cited by NDTV and The Hindu say.
Centre creating 'artificial scarcity' of COVID-19 vaccines: AAP
The AAP on Friday alleged that the Centre is creating artificial scarcity of COVID-19 vaccines to benefit Bharat Biotech and Serum Institute of India, a charge termed by the Delhi BJP as unfounded.
Government panel recommends 12-16 week gap between Covishield doses
A government expert panel has reportedly recommended raising the time gap between two doses of the COVID-19 vaccine Covishield to 12-16 weeks.
Coronavirus vaccine production to reach 9cr doses in June: Government
The Serum Institute of India and Bharat Biotech, the two companies India has entrusted to make its coronavirus vaccines, have both submitted their productions plans for the coming four months to the Indian government.
US looking to produce of J&J's COVID-19 vaccine in India
The United States is considering the production of Johnson & Johnson's COVID-19 vaccine in India along with ways to help manufacturers like the Serum Institute of India (SII) to boost production, Daniel B Smith, Charge d'Affaires of the US Embassy, said on Tuesday.
Give priority to Maharashtra in vaccine allocation: Tope to Poonawalla
Maharashtra Health Minister Rajesh Tope on Monday urged Serum Institute of India Chief Executive Officer Adar Poonawalla to give priority to the state in providing its anti-coronavirus vaccine, Covishield, as the government was ready to purchase doses from the Pune-based company.
SII given over Rs. 1,700cr for 11cr Covishield doses: Centre
The Health Ministry on Monday said that a 100 percent advance of Rs. 1732.50 crore was released to the Serum Institute of India on April 28 for 11 crore doses of Covishield vaccine during May, June, and July.
Getting aggressive calls from powerful people: SII CEO Adar Poonawalla
Serum Institute of India CEO Adar Poonawalla has revealed that his decision to fly to London when India is facing a COVID-19 second wave was largely due to the threats he had been facing.
Covishield price reduced to Rs. 300 for states: Adar Poonawalla
Adar Poonawalla, the CEO of the Serum Institute of India (SII), on Wednesday announced that the price of the COVID-19 vaccine Covishield was being reduced from Rs. 400 to Rs. 300 for states.
COVID-19: Government asks SII, Bharat Biotech to cut vaccine prices
The central government has asked the Serum Institute of India (SII) and Bharat Biotech to reduce the prices of their COVID-19 vaccines, PTI reported on Monday.
SII fixes Covishield's price at Rs. 600 for private hospitals
Serum Institute of India (SII) will sell Covishield at Rs. 400 per shot to states and at Rs. 600 to private hospitals, the Pune-based vaccine manufacturer said today.
We understand India's pharmaceutical requirements: Biden administration
The Biden administration has conveyed to New Delhi that it understands India's pharmaceutical requirements and promised to give the matter due consideration, observing that the current difficulty in the export of critical raw materials needed to manufacture COVID-19 vaccines is mainly due to an Act that forces American companies to prioritize domestic consumption.
India's Serum Institute refunds South Africa for undelivered coronavirus vaccines
Pune-based Serum Institute of India (SII) has fully refunded South Africa for 500,000 undelivered doses of the coronavirus vaccine, reports PTI.
AstraZeneca serves legal notice to Serum Institute over vaccine delays
Serum Institute of India (SII), the manufacturer of the coronavirus vaccine Covishield, has been served a legal notice by the drug maker AstraZeneca over delays in vaccine supply, the company's CEO Adar Poonawalla confirmed in an interview earlier this week.
Covishield 90% effective if doses given 2-3 months apart: Poonawalla
The efficacy of the COVID-19 vaccine Covishield could increase to 90% if the two doses are given 2.5-3 months apart, Serum Institute of India CEO Adar Poonawalla said Monday.
Serum CEO Poonawalla hopes to launch second vaccine by September
Serum Institute of India CEO Adar Poonawalla today said that his company hopes to launch its second coronavirus vaccine by September this year.
Amid growing cases, India temporarily halts export of AstraZeneca's vaccine
Facing a sudden spike in coronavirus cases, India has halted the export of the AstraZeneca vaccine for now, Reuters reported quoting two sources. Millions of doses of the vaccine are being manufactured by the Pune-based Serum Institute of India (SII), the world's biggest vaccine-maker.
SII to delay shipments to Brazil, Morocco, and Saudi Arabia
The Serum Institute of India (SII) will reportedly be delaying COVID-19 vaccine supplies to Brazil, Saudi Arabia, and Morocco amid criticism that India is not vaccinating enough people at home.
Delhi HC pulls up Centre for exporting COVID-19 vaccines
The Delhi High Court on Thursday pulled up the central government over restricted COVID-19 vaccinations in India, even as vaccine exports to other nations continue.